Cyclosporin A and Immunity in L1210 Leukaemia
Author Information
Author(s): L.M. Slater, M. Wetzel, J. Cho, P. Sweet
Primary Institution: University of California, Irvine
Hypothesis
Can cyclosporin A enhance the effectiveness of VP-16 therapy in producing immunity to L1210 leukaemia?
Conclusion
The addition of cyclosporin A to VP-16 therapy significantly prolongs survival and induces immunity to L1210 leukaemia in mice.
Supporting Evidence
- Cyclosporin A combined with VP-16 increased survival rates in mice with L1210 leukaemia.
- 60-day surviving mice treated with VP-16/CsA were immune to leukaemia rechallenge.
- Adoptive transfer of spleen cells from immune mice conferred immunity to untreated mice.
Takeaway
Researchers found that a drug called cyclosporin A can help mice fight off leukaemia better when used with another drug, VP-16.
Methodology
BDF/1 mice were treated with VP-16 alone or combined with cyclosporin A, and their survival was monitored and compared.
Limitations
The study primarily involved murine models, which may not fully translate to human responses.
Participant Demographics
BDF/1 mice were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website